ProQR Therapeutics Prices Public Offering, Private Placement

MT Newswires Live10-23

ProQR Therapeutics (PRQR) said late Tuesday it priced its previously announced public offering of 18 million ordinary shares at $3.50 per share for expected gross proceeds of $63 million.

Underwriters have been granted a 30-day option to buy up to 2.7 million additional shares.

Separately, the drug developer has entered into a share purchase agreement with Eli Lilly (LLY), wherein ProQR will offer Lilly 3.5 million shares to maintain its current pro rata ownership.

The transaction with Lilly is expected to yield about $12.3 million, subject to a purchase price cap of $15 million.

ProQR said it plans to use the proceeds from both the offering and the private placement, along with existing cash and cash equivalents, primarily to fund research and development and clinical development for current and future product candidates.

Price: 3.6001, Change: -0.18, Percent Change: -4.76

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment